Expansion of human Vα24+ NKT cells by repeated stimulation with KRN7000

被引:62
作者
Rogers, PR
Matsumoto, A
Naidenko, O
Kronenberg, M
Mikayama, T
Kato, S
机构
[1] Gemini Sci Inc, Res Lab, San Diego, CA 92121 USA
[2] La Jolla Inst Allergy & Immunol, San Diego, CA 92121 USA
[3] Kirin Brewery Co Ltd, Pharmaceut Res Lab, Gunma 3701295, Japan
关键词
natural killer T cell; KRN7000; galactosylceramide; V alpha 24; expansion; immunotherapy;
D O I
10.1016/j.jim.2003.12.003
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Changes in Valpha24(+)Vbeta11(+) NKT cell number and function are associated with human autoimmune diseases and cancer. Restoration of this corresponding NKT cell population in mice or in vivo activation with a-galactosylceramide (KRN7000) can prevent or reduce tumor growth and autoimmunity. Although the therapeutic value of these natural killer T (NKT) cells in man remains to be determined, large numbers of functional antigen-specific NKT cells can be expanded in vitro. We show that Valpha24(+)Vbeta11(+) human NKT cells are expanded by repeated stimulation with KRN7000, unfractionated donor peripheral blood mononuclear cells (PBMC), and recombinant human interleukin-2 (rhIL-2). NKT cells were expanded continuously for more than 2 months with a potential yield of >10(12) cells. The expanded NKT cells retained their CD4(+) or CD4(-) phenotype after restimulation and were functional as shown by cytokine secretion, killing of antigen-pulsed target cells, and activation of NK cell cytotoxicity. This expansion method may be useful for proof-of-concept studies involving adoptive transfer of ex vivo-expanded NKT cells as a new therapeutic option for cancer and autoimmune diseases. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:197 / 214
页数:18
相关论文
共 85 条
  • [1] Expansion of lung Vα14 NKT cells by administration of α-galactosylceramide-pulsed dendritic cells
    Akutsu, Y
    Nakayama, T
    Harada, M
    Kawano, T
    Motohashi, S
    Shimizu, E
    Ito, T
    Kamada, N
    Saito, T
    Matsubara, H
    Miyazawa, Y
    Ochiai, T
    Taniguchi, M
    [J]. JAPANESE JOURNAL OF CANCER RESEARCH, 2002, 93 (04): : 397 - 403
  • [2] Mouse CD1-specific NK1 T cells: Development, specificity, and function
    Bendelac, A
    Rivera, MN
    Park, SH
    Roark, JH
    [J]. ANNUAL REVIEW OF IMMUNOLOGY, 1997, 15 : 535 - 562
  • [3] CD1 RECOGNITION BY MOUSE NK1(+) T-LYMPHOCYTES
    BENDELAC, A
    LANTZ, O
    QUIMBY, ME
    YEWDELL, JW
    BENNINK, JR
    BRUTKIEWICZ, RR
    [J]. SCIENCE, 1995, 268 (5212) : 863 - 865
  • [4] In vivo identification of glycolipid antigen-specific T cells using fluorescent CD1d tetramers
    Benlagha, K
    Weiss, A
    Beavis, A
    Teyton, L
    Bendelac, A
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 191 (11) : 1895 - 1903
  • [5] BLUMBERG RS, 1991, J IMMUNOL, V147, P2518
  • [6] Overexpression of CD1d by keratinocytes in psoriasis and CD1d-dependent IFN-γ production by NK-T cells
    Bonish, B
    Jullien, D
    Dutronc, Y
    Huang, BB
    Modlin, R
    Spada, FM
    Porcelli, SA
    Nickoloff, BJ
    [J]. JOURNAL OF IMMUNOLOGY, 2000, 165 (07) : 4076 - +
  • [7] CD1d-mediated recognition of an α-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution
    Brossay, L
    Chioda, M
    Burdin, N
    Koezuka, Y
    Casorati, G
    Dellabona, P
    Kronenberg, M
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 188 (08) : 1521 - 1528
  • [8] Burdin N, 1998, J IMMUNOL, V161, P3271
  • [9] Human invariant Vαa24-JαQ TCR supports the development of CD1d-dependent NK1.1+ and NK1.1- T cells in transgenic mice
    Capone, M
    Cantarella, D
    Schümann, J
    Naidenko, OV
    Garavaglia, C
    Beermann, F
    Kronenberg, M
    Dellabona, P
    MacDonald, HR
    Casorati, G
    [J]. JOURNAL OF IMMUNOLOGY, 2003, 170 (05) : 2390 - 2398
  • [10] Carnaud C, 1999, J IMMUNOL, V163, P4647